» Articles » PMID: 28476872

Integrative Analysis Identifies a Novel AXL-PI3 Kinase-PD-L1 Signaling Axis Associated with Radiation Resistance in Head and Neck Cancer

Abstract

The primary cause of death due to head and neck squamous cell carcinoma (HNSCC) is local treatment failure. The goal of this study was to examine this phenomenon using an unbiased approach. We utilized human papilloma virus (HPV)-negative cell lines rendered radiation-resistant (RR) via repeated exposure to radiation, a panel of HPV-negative HNSCC cell lines and three cohorts of HPV-negative HNSCC tumors ( = 68, 97, and 114) from patients treated with radiotherapy and subjected to genomic, transcriptomic, and proteomic analysis. RR cell lines exhibited upregulation of several proteins compared with controls, including increased activation of Axl and PI3 kinase signaling as well as increased expression of PD-L1. Additionally, inhibition of either Axl or PI3 kinase led to decreased PD-L1 expression. When clinical samples were subjected to RPPA and mRNA expression analysis, PD-L1 was correlated with both Axl and PI3K signaling as well as dramatically associated with local failure following radiotherapy. This finding was confirmed examining a third cohort using immunohistochemistry. Indeed, tumors with high expression of PD-L1 had failure rates following radiotherapy of 60%, 70%, and 50% compared with 20%, 25%, and 20% in the PD-L1-low expression group ( = 0.01, 1.9 × 10, and 9 × 10, respectively). This finding remained significant on multivariate analysis in all groups. Additionally, patients with PD-L1 low/CD8 tumor-infiltrating lymphocytes high had no local failure or death due to disease ( = 5 × 10 and = 4 × 10, respectively). Taken together, our data point to a targetable Axl-PI3 kinase-PD-L1 axis that is highly associated with radiation resistance. .

Citing Articles

AXL signaling in cancer: from molecular insights to targeted therapies.

Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L Signal Transduct Target Ther. 2025; 10(1):37.

PMID: 39924521 PMC: 11808115. DOI: 10.1038/s41392-024-02121-7.


Advances in nanoparticle-based radiotherapy for cancer treatment.

He M, Chen S, Yu H, Fan X, Wu H, Wang Y iScience. 2025; 28(1):111602.

PMID: 39834854 PMC: 11743923. DOI: 10.1016/j.isci.2024.111602.


AXL: shapers of tumor progression and immunosuppressive microenvironments.

Liu Y, Xu L, Dou Y, He Y Mol Cancer. 2025; 24(1):11.

PMID: 39799359 PMC: 11724481. DOI: 10.1186/s12943-024-02210-9.


RNAi Screen Identifies AXL Inhibition Combined with Cannabinoid WIN55212-2 as a Potential Strategy for Cancer Treatment.

Li F, Gong H, Jia X, Gao C, Jia P, Zhao X Pharmaceuticals (Basel). 2024; 17(11).

PMID: 39598377 PMC: 11597789. DOI: 10.3390/ph17111465.


Advanced Human Papillomavirus-Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies.

Park R, Chung C Mol Cancer Ther. 2024; 23(12):1717-1730.

PMID: 39301607 PMC: 11612620. DOI: 10.1158/1535-7163.MCT-24-0281.


References
1.
Herbst R, Soria J, Kowanetz M, Fine G, Hamid O, Gordon M . Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014; 515(7528):563-7. PMC: 4836193. DOI: 10.1038/nature14011. View

2.
Ahmadzadeh M, Johnson L, Heemskerk B, Wunderlich J, Dudley M, White D . Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009; 114(8):1537-44. PMC: 2927090. DOI: 10.1182/blood-2008-12-195792. View

3.
Marie-Egyptienne D, Lohse I, Hill R . Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2012; 341(1):63-72. DOI: 10.1016/j.canlet.2012.11.019. View

4.
Atefi M, Avramis E, Lassen A, Wong D, Robert L, Foulad D . Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin Cancer Res. 2014; 20(13):3446-57. PMC: 4079734. DOI: 10.1158/1078-0432.CCR-13-2797. View

5.
Harari P, Harris J, Kies M, Myers J, Jordan R, Gillison M . Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. J Clin Oncol. 2014; 32(23):2486-95. PMC: 4121506. DOI: 10.1200/JCO.2013.53.9163. View